[Bucharest, October,14, 2024] – ZayaAI, a pioneer in AI-driven solutions for healthcare, is thrilled to announce the addition of Kimberly Gasuad to its Board of Directors. Kimberly brings extensive experience in business development, strategic partnerships, and healthcare technology, having previously served as Senior Vice President of Business Development & Strategy at Ibex Medical Analytics.
With a proven track record of securing multi-million-dollar contracts and fostering strategic alliances with top-tier pharmaceutical companies and healthcare providers, Kimberly’s expertise aligns perfectly with ZayaAI’s vision for expansion and innovation. Her experience spans leadership roles at Roche, McKesson, and Novartis, where she developed go-to-market strategies and drove digital pathology and AI adoption.
Cristian Mogodici, CEO of ZayaAI, expressed his excitement, stating, “Kimberly’s exceptional leadership and business development expertise will be invaluable as ZayaAI continues its trajectory of growth in the AI healthcare space. Her insights and strategic acumen will significantly enhance our mission to deliver groundbreaking AI solutions.”
Kimberly Gasuad added, “I’m excited to join the ZayaAI Board of Directors and contribute to a company at the forefront of AI innovation in healthcare. I look forward to supporting ZayaAI’s continued success and helping to accelerate its impact on the global healthcare industry.”
About ZayaAI
ZayaAI equips pathologists and researchers in clinical labs with powerful deep-learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud-based ZayaAI products and services aim to improve the efficiency and precision of pathology diagnosis and pathology image analysis beyond current capabilities, across a variety of fields from oncology to dermato-pathology and more.